Omnicell (OMCL) Stock Price
Omnicell Price
Revenue has compounded at 11.3% per year over the past 19 years to 1.18 B USD. Earnings per share have declined at 10.3% per year over the last 19 years. Omnicell's net margin stands at 0.2%, down from 6.9% several years earlier. Analysts set a median price target of 57.50 USD, implying 57.8% above the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus.
Omnicell stock price
Omnicell business model & stock analysis
Frequently asked questions about Omnicell
Omnicell Inc is a leading healthcare technology company specializing in medication and supply management solutions. The company's business model revolves around providing automated systems and software solutions to hospitals, pharmacies, and other healthcare institutions. Omnicell aims to streamline workflow, improve patient safety, and optimize inventory management through its innovative technology and services. By offering a comprehensive suite of products, including medication dispensing cabinets, inventory management systems, and analytics software, Omnicell enhances operational efficiency and patient care quality. With its patient-centric approach, Omnicell Inc continues to be a trusted partner in the healthcare industry, delivering valuable solutions and improving overall healthcare outcomes.
Omnicell Inc is primarily active in the healthcare industry.
Omnicell Inc faces competition from various companies in the market. Some of its main competitors include McKesson Corporation, BD (Becton, Dickinson and Company), and Cantel Medical Corp. These companies operate in the healthcare solutions industry and provide similar products and services, which directly compete with Omnicell Inc. Additionally, companies like Capsa Healthcare and Baxter International Inc. also pose competition in certain segments. However, Omnicell Inc's strong market presence, innovative technologies, and comprehensive range of solutions help them remain competitive in the industry.
Omnicell Inc, a leading provider of medication management solutions, has a rich history and background. Established in 1992, Omnicell has continuously delivered innovative technologies to enhance patient safety and improve healthcare outcomes. The company's journey started with automated dispensing systems for medication storage and administration. Over the years, Omnicell expanded its product portfolio to include advanced solutions like robotic automation, analytics, and interoperability, catering to various healthcare settings globally. Today, Omnicell is renowned for its commitment to optimizing medication management processes, reducing errors, improving efficiency, and enabling healthcare professionals to focus on patient care. With a strong track record and dedication to innovation, Omnicell Inc has established itself as a trusted name in the healthcare industry.
Omnicell Inc has achieved several significant milestones since its inception. The company has become a global leader in automated healthcare solutions, catering to hospitals, pharmacies, and healthcare organizations. Omnicell's product portfolio includes advanced medication management systems, robotics, and software solutions improving patient safety and operational efficiency. The company has successfully expanded its global presence, established strategic partnerships, and received multiple industry accolades. Moreover, Omnicell has consistently focused on research and development, resulting in innovative technologies and improved patient outcomes. With its dedication to advancing healthcare through technology, Omnicell Inc continues to drive positive change in the industry.
Omnicell Inc is primarily present in the United States.
Omnicell Inc represents a strong commitment to improving patient care and safety through innovative medication management solutions. The company's corporate philosophy revolves around optimizing workflows and ensuring the right medication is delivered to the right patient at the right time. Omnicell is dedicated to enhancing operational efficiency, reducing medication errors, and promoting adherence to medication regimens. Their values include prioritizing patient-centricity, fostering a culture of collaboration, and driving continuous innovation in healthcare technology. Omnicell Inc strives to revolutionize medication management processes, ultimately helping healthcare organizations deliver better patient outcomes and improve overall healthcare efficiency.
Analysts currently set an average price target of 57.50 USD for the Omnicell stock (median: 57.50 USD), implying +57.8 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Omnicell stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Omnicell to generate revenue of 1.24 B USD and earnings per share of 2.29 USD.
Converted at the current exchange rate, the Omnicell share trades at 32.57 EUR (36.45 USD).
The Omnicell share (OMCL) is listed on 5 stock exchanges, including: NASDAQ (OMCL), SIX (Zürich) (OC9.SW), Frankfurt (OC9.F), München (OC9.MU), Düsseldorf (OC9.DU).
Omnicell Inc. is a US-based company that has gained worldwide recognition for its automation solutions for healthcare providers. The company positions itself as a reliable provider of innovative products and services in this field. The main products and services of Omnicell Inc. fall into four main areas: medication management, central pharmacy systems, workflow optimization, and analytics solutions. The medication management is the core of Omnicell Inc.'s business model. The company offers a variety of solutions for various areas including hospitals, pharmacies, and long-term care facilities to better automate medication inspection, preparation, dispensing, and returns. These solutions help nursing staff save time, minimize errors, and better meet patient needs. Central pharmacy systems are another important pillar of Omnicell Inc. These systems are designed to automate the workflow of pharmacies and distribution centers by monitoring and managing inventory and orders, optimizing product assignment to patients, and providing real-time data for inventory management. Workflow optimization is an important aspect of Omnicell Inc.'s business model. The company aims to increase the efficiency of nursing staff by automating workflows, reducing workload, and improving the quality of patient care. The company has developed a wide range of solutions for this purpose, including automated documentation, inventory management, and patient assignment. Analytics solutions also play an important role in Omnicell Inc.'s business strategy. The company offers innovative analysis tools that monitor prescription dispensing and collect data to optimize medication inventory and orders. These tools provide important business-relevant information that contributes to higher ROI in the healthcare industry. Overall, the company offers a wide range of products and services aimed at increasing efficiency, accuracy, and effectiveness in healthcare. Omnicell Inc. aims to meet the needs of providers and patients alike while ensuring the highest level of reliability, efficiency, and safety. With its innovative products, strong focus on customer service, and continuous investment in research and development, Omnicell Inc. has established itself as a market leader in automation solutions for healthcare providers.
The expected revenue of Omnicell is 1.24 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Omnicell is 103.09 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Omnicell is currently 15.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Omnicell stock.
The price-to-sales ratio (P/S) of Omnicell is currently 1.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Omnicell stock.
The Eulerpool Quality Score for Omnicell is 3/10.
The ISIN of Omnicell is US68213N1090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Omnicell is 632313. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Omnicell is OMCL. The ticker symbol is used to trade Omnicell shares on the stock exchange.
Omnicell stock
Omnicell Peer Group
Omnicell Ticker
Omnicell FIGI
All fundamentals and in-depth analysis of Omnicell
Our stock analysis for Omnicell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Omnicell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.